Table 1.
Pharmacological Costs of the Triple Therapy (MITT)
| Combination | Market Share | Daily Cost, € | ||
|---|---|---|---|---|
| LABA/ICS + LAMA | Trade name | % group: 81% | Individual | Weighted |
| Salmeterol/fluticasone | Seretide | 39.9% | 1.376 | 2.80 |
| Formoterol/budesonide | Symbicort | 20.5% | 1.542 | |
| Beclometasone/formoterol | Fostair | 23.8% | 1.589 | |
| Vilanterol/fluticasone | Relvar | 15.8% | 1.589 | |
| Tiotropium | Spiriva | 100.0% | 1.308 | |
| LAMA/LABA + ICS | % group: 19% | Individual | Weighted | |
| Indacaterol/glycopyrronium | Ultibro | 44.7% | 2.652 | 3.02 |
| Olodaterol/tiotropium | Spiolto | 32.9% | 2.513 | |
| Umeclidinium/vilanterol | Anoro | 5.6% | 2.166 | |
| Aclidinium/formoterol | Duaklir | 16.8% | 2.166 | |
| Budesonide | Pulmicort | 100.0% | 0.526 | |
| Weighted daily cost for MITT | 2.84 | |||